MBA MBA - Adaptive Biotechnologies CEO CoFounder
| ADPT Stock | USD 7.75 0.11 1.40% |
Insider
MBA MBA is CEO CoFounder of Adaptive Biotechnologies Corp
| Age | 50 |
| Phone | 206 659 0067 |
| Web | https://www.adaptivebiotech.com |
Adaptive Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.1637) % which means that it has lost $0.1637 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6676) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies' management efficiency ratios could be used to measure how well Adaptive Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Marc Harrison | Legend Biotech Corp | N/A | |
| Jason MBA | Caribou Biosciences | 56 | |
| Alexis Komor | Beam Therapeutics | N/A | |
| Gloria Lin | Krystal Biotech | N/A | |
| RPh PharmD | Elevation Oncology | 40 | |
| Johanna FriedlNaderer | Vir Biotechnology | 56 | |
| Cedric MD | Apellis Pharmaceuticals | 53 | |
| MD MPH | Verve Therapeutics | N/A | |
| David Glynn | Krystal Biotech | N/A | |
| Justin Skoble | Caribou Biosciences | N/A | |
| Shanna Peek | Sana Biotechnology | N/A | |
| Allison Dorval | Verve Therapeutics | 48 | |
| Issi MBA | Verve Therapeutics | N/A | |
| Lawrence MD | Vir Biotechnology | 77 | |
| Peter Facchini | Enveric Biosciences | 61 | |
| Brittany Mccleery | Sana Biotechnology | N/A | |
| Louis MD | Vir Biotechnology | N/A | |
| Rachel Haurwitz | Caribou Biosciences | 39 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Ying Huang | Legend Biotech Corp | 52 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.16 |
Adaptive Biotechnologies Leadership Team
Elected by the shareholders, the Adaptive Biotechnologies' board of directors comprises two types of representatives: Adaptive Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptive. The board's role is to monitor Adaptive Biotechnologies' management team and ensure that shareholders' interests are well served. Adaptive Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptive Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yi Zhou, Chief Officer | ||
| Tycho Peterson, Chief Officer | ||
| Stacy JD, General VP | ||
| Harlan Robins, Co-Founder, Chief Scientific Officer | ||
| Kyle Piskel, Principal Officer | ||
| Susan Bobulsky, Chief MRD | ||
| Stacy Taylor, General VP | ||
| Mark Adams, Chief Officer | ||
| Julie Rubinstein, President COO | ||
| Francis Lo, Chief Officer | ||
| Sharon Benzeno, Chief Medicine | ||
| Karina Calzadilla, Vice Relations | ||
| Chad MBA, CEO CoFounder | ||
| Nitin Sood, Chief MRD | ||
| MBA MBA, CEO CoFounder | ||
| Mary Lancelotta, Senior BioPharma | ||
| Christopher Carlson, Founder |
Adaptive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adaptive Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 992.24 M | ||||
| Shares Outstanding | 147.58 M | ||||
| Shares Owned By Insiders | 1.92 % | ||||
| Shares Owned By Institutions | 90.70 % | ||||
| Number Of Shares Shorted | 8.66 M | ||||
| Price To Earning | 0.25 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.